Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis

Ernst-Wilhelm Radue; William H Stuart; Peter A Calabresi; Christian Confavreux; Steven L Galetta; Richard A Rudick; Fred D Lublin; Bianca Weinstock-Guttman; Daniel R Wynn; Elizabeth Fisher; Athina Papadopoulou; Frances Lynn; Michael A Panzara; Alfred W Sandrock; SENTINEL Investigators; Per Soelberg Sørensen; Morten Bjørn Blinkenberg

doi:10.1016/j.jns.2010.02.012

Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis

Ernst-Wilhelm Radue, William H Stuart, Peter A Calabresi, Christian Confavreux, Steven L Galetta, Richard A Rudick, Fred D Lublin, Bianca Weinstock-Guttman, Daniel R Wynn, Elizabeth Fisher, Athina Papadopoulou, Frances Lynn, Michael A Panzara, Alfred W Sandrock, SENTINEL Investigators, Per Soelberg Sørensen, Morten Bjørn Blinkenberg

Institut for Klinisk Medicin

44 Citationer (Scopus)

Abstract

The SENTINEL study showed that the addition of natalizumab improved outcomes for patients with relapsing multiple sclerosis (MS) who had experienced disease activity while receiving interferon beta-1a (IFNβ-1a) alone. Previously unreported secondary and tertiary magnetic resonance imaging (MRI) measures are presented here. Patients received natalizumab 300 mg (n = 589) or placebo (n = 582) intravenously every 4 weeks plus IFNβ-1a 30 μg intramuscularly once weekly. Annual MRI scans allowed comparison of a range of MRI end points versus baseline. Over 2 years, 67% of patients receiving natalizumab plus IFNβ-1a remained free of new or enlarging T2-lesions compared with 30% of patients receiving IFNβ-1a alone. The mean change from baseline in T2 lesion volume over 2 years decreased in patients receiving natalizumab plus IFNβ-1a and increased in those receiving IFNβ-1a alone (-277.5 mm³ versus 525.6 mm³; p < 0.001). Compared with IFNβ-1a alone, add-on natalizumab therapy resulted in a smaller increase in mean T1-hypointense lesion volume after 2 years (1821.3 mm³ versus 2210.5 mm³; p < 0.001), a smaller mean number of new T1-hypointense lesions over 2 years (2.3 versus 4.1; p < 0.001), and a slower rate of brain atrophy during the second year of therapy (-0.31% versus -0.40%; p = 0.020). Natalizumab add-on therapy reduced gadolinium-enhancing, T1-hypointense, and T2 MRI lesion activity and slowed brain atrophy progression in patients with relapsing MS who experienced disease activity despite treatment with IFNβ-1a alone.

Originalsprog	Engelsk
Tidsskrift	Journal of the Neurological Sciences
Vol/bind	292
Udgave nummer	1-2
Sider (fra-til)	28-35
Antal sider	8
ISSN	0022-510X
DOI	https://doi.org/10.1016/j.jns.2010.02.012
Status	Udgivet - 15 maj 2010

Adgang til dokumentet

10.1016/j.jns.2010.02.012

Citationsformater

Radue, E.-W., Stuart, W. H., Calabresi, P. A., Confavreux, C., Galetta, S. L., Rudick, R. A., Lublin, F. D., Weinstock-Guttman, B., Wynn, D. R., Fisher, E., Papadopoulou, A., Lynn, F., Panzara, M. A., Sandrock, A. W., SENTINEL Investigators, Sørensen, P. S., & Blinkenberg, M. B. (2010). Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. Journal of the Neurological Sciences, 292(1-2), 28-35. https://doi.org/10.1016/j.jns.2010.02.012

Radue, E-W, Stuart, WH, Calabresi, PA, Confavreux, C, Galetta, SL, Rudick, RA, Lublin, FD, Weinstock-Guttman, B, Wynn, DR, Fisher, E, Papadopoulou, A, Lynn, F, Panzara, MA, Sandrock, AW, SENTINEL Investigators, Sørensen, PS & Blinkenberg, MB 2010, 'Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis', Journal of the Neurological Sciences, bind 292, nr. 1-2, s. 28-35. https://doi.org/10.1016/j.jns.2010.02.012

@article{7a9c464864c84a13a514e9d5dc905885,

title = "Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis",

abstract = "The SENTINEL study showed that the addition of natalizumab improved outcomes for patients with relapsing multiple sclerosis (MS) who had experienced disease activity while receiving interferon beta-1a (IFNβ-1a) alone. Previously unreported secondary and tertiary magnetic resonance imaging (MRI) measures are presented here. Patients received natalizumab 300 mg (n = 589) or placebo (n = 582) intravenously every 4 weeks plus IFNβ-1a 30 μg intramuscularly once weekly. Annual MRI scans allowed comparison of a range of MRI end points versus baseline. Over 2 years, 67% of patients receiving natalizumab plus IFNβ-1a remained free of new or enlarging T2-lesions compared with 30% of patients receiving IFNβ-1a alone. The mean change from baseline in T2 lesion volume over 2 years decreased in patients receiving natalizumab plus IFNβ-1a and increased in those receiving IFNβ-1a alone (-277.5 mm3 versus 525.6 mm3; p < 0.001). Compared with IFNβ-1a alone, add-on natalizumab therapy resulted in a smaller increase in mean T1-hypointense lesion volume after 2 years (1821.3 mm3 versus 2210.5 mm3; p < 0.001), a smaller mean number of new T1-hypointense lesions over 2 years (2.3 versus 4.1; p < 0.001), and a slower rate of brain atrophy during the second year of therapy (-0.31% versus -0.40%; p = 0.020). Natalizumab add-on therapy reduced gadolinium-enhancing, T1-hypointense, and T2 MRI lesion activity and slowed brain atrophy progression in patients with relapsing MS who experienced disease activity despite treatment with IFNβ-1a alone.",

author = "Ernst-Wilhelm Radue and Stuart, {William H} and Calabresi, {Peter A} and Christian Confavreux and Galetta, {Steven L} and Rudick, {Richard A} and Lublin, {Fred D} and Bianca Weinstock-Guttman and Wynn, {Daniel R} and Elizabeth Fisher and Athina Papadopoulou and Frances Lynn and Panzara, {Michael A} and Sandrock, {Alfred W} and S{\o}rensen, {Per Soelberg} and S{\o}rensen, {Per Soelberg} and Blinkenberg, {Morten Bj{\o}rn}",

year = "2010",

month = may,

day = "15",

doi = "10.1016/j.jns.2010.02.012",

language = "English",

volume = "292",

pages = "28--35",

journal = "Journal of the Neurological Sciences",

issn = "0022-510X",

publisher = "Elsevier",

number = "1-2",

}

TY - JOUR

T1 - Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis

AU - Radue, Ernst-Wilhelm

AU - Stuart, William H

AU - Calabresi, Peter A

AU - Confavreux, Christian

AU - Galetta, Steven L

AU - Rudick, Richard A

AU - Lublin, Fred D

AU - Weinstock-Guttman, Bianca

AU - Wynn, Daniel R

AU - Fisher, Elizabeth

AU - Papadopoulou, Athina

AU - Lynn, Frances

AU - Panzara, Michael A

AU - Sandrock, Alfred W

AU - SENTINEL Investigators

AU - Sørensen, Per Soelberg

AU - Blinkenberg, Morten Bjørn

PY - 2010/5/15

Y1 - 2010/5/15

N2 - The SENTINEL study showed that the addition of natalizumab improved outcomes for patients with relapsing multiple sclerosis (MS) who had experienced disease activity while receiving interferon beta-1a (IFNβ-1a) alone. Previously unreported secondary and tertiary magnetic resonance imaging (MRI) measures are presented here. Patients received natalizumab 300 mg (n = 589) or placebo (n = 582) intravenously every 4 weeks plus IFNβ-1a 30 μg intramuscularly once weekly. Annual MRI scans allowed comparison of a range of MRI end points versus baseline. Over 2 years, 67% of patients receiving natalizumab plus IFNβ-1a remained free of new or enlarging T2-lesions compared with 30% of patients receiving IFNβ-1a alone. The mean change from baseline in T2 lesion volume over 2 years decreased in patients receiving natalizumab plus IFNβ-1a and increased in those receiving IFNβ-1a alone (-277.5 mm3 versus 525.6 mm3; p < 0.001). Compared with IFNβ-1a alone, add-on natalizumab therapy resulted in a smaller increase in mean T1-hypointense lesion volume after 2 years (1821.3 mm3 versus 2210.5 mm3; p < 0.001), a smaller mean number of new T1-hypointense lesions over 2 years (2.3 versus 4.1; p < 0.001), and a slower rate of brain atrophy during the second year of therapy (-0.31% versus -0.40%; p = 0.020). Natalizumab add-on therapy reduced gadolinium-enhancing, T1-hypointense, and T2 MRI lesion activity and slowed brain atrophy progression in patients with relapsing MS who experienced disease activity despite treatment with IFNβ-1a alone.

AB - The SENTINEL study showed that the addition of natalizumab improved outcomes for patients with relapsing multiple sclerosis (MS) who had experienced disease activity while receiving interferon beta-1a (IFNβ-1a) alone. Previously unreported secondary and tertiary magnetic resonance imaging (MRI) measures are presented here. Patients received natalizumab 300 mg (n = 589) or placebo (n = 582) intravenously every 4 weeks plus IFNβ-1a 30 μg intramuscularly once weekly. Annual MRI scans allowed comparison of a range of MRI end points versus baseline. Over 2 years, 67% of patients receiving natalizumab plus IFNβ-1a remained free of new or enlarging T2-lesions compared with 30% of patients receiving IFNβ-1a alone. The mean change from baseline in T2 lesion volume over 2 years decreased in patients receiving natalizumab plus IFNβ-1a and increased in those receiving IFNβ-1a alone (-277.5 mm3 versus 525.6 mm3; p < 0.001). Compared with IFNβ-1a alone, add-on natalizumab therapy resulted in a smaller increase in mean T1-hypointense lesion volume after 2 years (1821.3 mm3 versus 2210.5 mm3; p < 0.001), a smaller mean number of new T1-hypointense lesions over 2 years (2.3 versus 4.1; p < 0.001), and a slower rate of brain atrophy during the second year of therapy (-0.31% versus -0.40%; p = 0.020). Natalizumab add-on therapy reduced gadolinium-enhancing, T1-hypointense, and T2 MRI lesion activity and slowed brain atrophy progression in patients with relapsing MS who experienced disease activity despite treatment with IFNβ-1a alone.

U2 - 10.1016/j.jns.2010.02.012

DO - 10.1016/j.jns.2010.02.012

M3 - Journal article

SN - 0022-510X

VL - 292

SP - 28

EP - 35

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

IS - 1-2

ER -

Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater